Navigation Links
Carrington's DelSite Presentation at Rodman & Renshaw Conference to be Webcast Live on November 7th
Date:11/5/2007

IRVING, Texas, Nov. 5 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (OTC Bulletin Board: CARN) today said the upcoming presentation on DelSite Biotechnologies, Inc., its wholly-owned subsidiary, will be webcast live from the Kennedy I Room at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference at New York City's Palace Hotel on Wednesday, November 7th, at 2:00 pm Eastern Time.

The presentation will cover DelSite's three key platform technologies in the areas of drug delivery and vaccine adjuvants. The Company will also provide an update on the development status of DelSite's lead product candidate. To access the webcast, please log on to the following website: http://www.wsw.com/webcast/rrshq12/carn.pk.

DelSite Biotechnologies specializes in the development of novel liquid and powder formulations for protein/peptide therapeutics and vaccines using its proprietary platform technologies. So far this year, DelSite has signed six technology rights evaluation agreements with commercial partners and institutions that are interested in its delivery technology.

About Carrington

Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com.

About Rodman & Renshaw, LLC

Rodman & Renshaw is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. It also provides research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital-intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.

Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission.


'/>"/>
SOURCE Carrington Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Carrington Subsidiary DelSite to Present at International Vaccine Conference in Ireland
2. Carrington Subsidiary DelSite to Present at Investor Conference
3. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
4. Bear Stearns 20th Annual Healthcare Conference to Webcast Millennium Presentation
5. Exelixis Announces September 18 Webcast of Presentation at the Bank of America 2007 Investment Conference
6. Rohm and Haas to Webcast Presentation at Credit Suisse Chemicals Conference
7. Haemonetics Webcast Presentation
8. Presentation at Bio Contact Quebec 2007
9. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
10. Accuray to Webcast Senior Management Presentations at Analyst Day Event
11. CareTech Solutions Executive to Conduct Presentation on Creating a Healthy Revenue Cycle at AHIMA Convention and Exhibit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... ... 29, 2017 , ... Saturday, April 29, marks World Veterinary ... have on animal health and welfare as well as on public health. The ... a theme each year and this year have selected “Antimicrobial Resistance—From Awareness to ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... It's not ... are a number of illnesses that are unclear as to whether or not they ... heads. Bronchitis is one of these illnesses. So, FindaTopDoc took a look into the ...
(Date:4/28/2017)... ... ... much more than energy – it also has mental and physical benefits. According to the ... which can increase the risk of having a car accident. , This week is ... help you sleep better and feel better:, , Turn off all ...
(Date:4/28/2017)... VA (PRWEB) , ... April 28, 2017 , ... The ... volunteer board members and officers for 2017-2018. The annual board election process has been ... on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, ...
(Date:4/28/2017)... Md. (PRWEB) , ... April 28, 2017 , ... ... Association of America (UCAOA) and College of Urgent Care Medicine will host industry ... workshops, sessions and speakers will help those in the industry adapt to the ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 ... an immune response in pets such as canine, ... are of various types such as Attenuated Live ... Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated live ... virus or bacteria, which have been weakend under ...
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... 1 fiscal 2017 earnings per share (EPS) guidance ... 2019.  This is in conjunction with this morning,s announcement ... Vein Thrombosis and Nutritional Insufficiency businesses. Cardinal ... continuing operations will be at the bottom of its ...
(Date:4/18/2017)... -- Astute Medical, Inc., developer of biomarkers for better healthcare, ... the 2017 National Kidney Foundation (NKF) Spring Clinical ... 22. Physicians will present data on two biomarkers, ... acute kidney injury (AKI) during the management of patients ... Elevated levels of TIMP-2 and IGFBP-7 have been shown ...
Breaking Medicine Technology: